The Max Foundation hosts webinar on 25 years of CML targeted therapy
Updated
Updated · Oncodaily · May 9
The Max Foundation hosts webinar on 25 years of CML targeted therapy
4 articles · Updated · Oncodaily · May 9
Chief executive Pat Garcia-Gonzalez said the event is on 11 May, marking 25 years since the first tyrosine kinase inhibitor for chronic myeloid leukemia was approved on 10 May 2001.
She said targeted therapy transformed CML from a fatal disease into a manageable one, while highlighting advances in patient advocacy, diagnostics, monitoring and long-term care.
The foundation says major gaps remain in molecular monitoring, treatment adherence and survivorship care in both high- and low-income settings, and is urging renewed commitment to optimal care worldwide.
After 25 years of turning CML into a manageable disease, are we finally on the brink of a universal cure?
A life-saving CML pill is now cheap and generic. Why do patients worldwide still face deadly gaps in care?